Vifor : FDA Approves Korsuva Injection To Treat Moderate-to-severe Pruritus In Hemodialysis Patients

The U.S. Food and Drug Administration has approved Korsuva or difelikefalin for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis, Vifor Pharma and Cara Therapeutics (CARA) said in a statement on Tuesday.

Vifor Pharma expects to begin to market Korsuva injection in the first-quarter of 2022 with reimbursement expected in the first-half of 2022.

Korsuva injection is a first-in-class kappa opioid receptor agonist that targets the body's peripheral nervous system.

The companies have agreed to an exclusive license to commercialize Korsuva injection in the United States. The agreement features a Cara 60%, Vifor Pharma 40% profit-sharing arrangement in non-Fresenius Medical Care clinics in the U.S.

As per a previous deal, Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics have agreed to market KORSUVA injection to Fresenius Medical Care North America dialysis clinics in the U.S. under a Cara 50%, Vifor Pharma 50% profit-sharing arrangement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT